Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Costs, Cognitive Abilities and Quality of Life After Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement (CCQ)

11 novembre 2016 mis à jour par: Francesco Saia, MD, PhD, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Multicenter, prospective, observational study in aortic stenosis (AS) patients undergoing transcatheter aortic valve implantation (TAVI) or high-risk patients undergoing aortic valve replacement (AVR).

The objectives of the study are:

  1. Description of neurocognitive status before and after transcatheter aortic valve implantation and aortic valve replacement procedures
  2. Description of Quality of Life (QoL) after these procedures
  3. Defining the relevance of baseline psychological, emotional and cognitive factors on the outcomes associated to the different treatment modalities
  4. Assessment of costs associated to each of the above mentioned strategies of treatment, including costs of the index hospitalization and costs of follow-up.

Aperçu de l'étude

Description détaillée

In Italy, a nation-wide observational study endorsed by the Superior Institute of Health has been previously launched in order to evaluate appropriateness and effectiveness of aortic valve replacement (AVR) and transcatheter aortic valve implantation (TAVI) procedures: the OBservational Study of Effectiveness of AVR-TAVI procedures for severe Aortic steNosis Treatment (OBSERVANT). The present study was designed to complement the national survey on TAVI and AVR procedures including data about costs, cognitive functions and quality of life after these procedures. This integrated framework may help defining the relevance of baseline psychological, emotional and cognitive factors on the outcomes associated to the different treatment modalities and, on the other hand, should enable accurate evaluation of the impact of each kind of treatment on quality of life and neuropsychological functions. These elements could also represent relevant keys to decision-making to the different therapeutic strategies. In addition, we aim to ascertain costs associated to each of the above mentioned strategies of treatment, including costs of the index hospitalization and follow-up costs. Costs estimate, combined to the integrated physical and mental health status outcome for each treatment modality, may represent the background for subsequent cost-effectiveness analyses.

All consecutive patients undergoing transcatheter aortic valve implantation or aortic valve replacement (if age ≥ 80 years or Logistic Euroscore ≥ 15%) for aortic stenosis at participating centers during the period of enrollment will be included in the registry, after release of written informed consent. Allocation of patients to different treatment groups will be performed jointly by a cardiologist and a cardiac surgeon on the basis of a complete clinical framework, independently from the present study and in accordance with available guidelines. Type of treatment (for example, access site for TAVI, type of prosthesis…) will be decided by the physicians based on local clinical practice and general principles of good clinical practice.

The administration of neurocognitive and quality of life questionnaires will be performed before the procedure and after 3 months and 1 year by trained personnel following standard operation procedures defined by a coordinating unit. A telephone and web-based support for operators will be available throughout the entire duration of the study. A common methodology for data collection and analysis is defined to guarantee data reliability and homogeneity of assessments among the participating units. The cost analysis will be coordinated by the Regional Healthcare and Social Agency of the Emilia Romagna Region.

Data will be collected in a web-based database (OBSERVANT) through dedicated Case Records Forms and a final database will be built by merging this database with a separate database for costs and Hospital Discharge Records and Mortality Registry databases.

Type d'étude

Observationnel

Inscription (Réel)

518

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Bologna, Italie, 40138
        • Institute of Cardiology, Azienda Ospedaliero-Universitaria di Bologna

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant
  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

All consecutive patients undergoing TAVI or AVR for AS at participating centers during the period of enrollment

La description

Inclusion Criteria:

  • All consecutive patients undergoing TAVI at participating centers during the period of enrollment
  • All consecutive patients aged ≥80 years or with Logistic Euroscore ≥15% undergoing AVR at participating centers during the period of enrollment

Exclusion Criteria:

  • Absence of informed consent

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: Cohorte
  • Perspectives temporelles: Éventuel

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Transcatheter aortic valve implantation
All consecutive patients undergoing TAVI at participating centres during study period
Patients undergoing TAVI with transfemoral, transapical, or any other vascular access
Autres noms:
  • Edwards Sapien XT
  • Corevalve
  • Acurate-TA
Aortic Valve Replacement
All consecutive patients aged ≥ 80 years or with Logistic Euroscore≥ 15% undergoing AVR for AS at participating centers during the period of enrollment
Surgical AVR, with all kind of commercially available prosthesis (stented, stentless, mechanical)

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Mini Mental State Examination (MMSE)
Délai: baseline, 3-month, 12-month
Changes in cognitive function after transcatheter aortic valve implantation and surgical aortic valve replacement
baseline, 3-month, 12-month
Hospital Anxiety and Depression Scale (HADS)
Délai: baseline, 3-month, 12-month
Changes of emotional status after transcatheter aortic valve implantation and surgical aortic valve replacement
baseline, 3-month, 12-month
Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Délai: baseline, 3-month, 12-month
Changes in quality of life after transcatheter aortic valve implantation and surgical aortic valve replacement
baseline, 3-month, 12-month
In-hospital costs
Délai: Participants will be followed for the duration of hospital stay, an expected average of 10 days for transcatheter aortic valve implantation and 2 weeks for surgical Aortic Valve Replacement
Calculation of precise hospital costs for transcatheter aortic valve implantation and surgical Aortic Valve Replacement, including costs of hospitalization, drugs and devices.
Participants will be followed for the duration of hospital stay, an expected average of 10 days for transcatheter aortic valve implantation and 2 weeks for surgical Aortic Valve Replacement

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Myocardial infarction
Délai: 30-day, 12-month and up to 2-year (longest available follow-up)
Incidence of myocardial infarction
30-day, 12-month and up to 2-year (longest available follow-up)
Stroke
Délai: 30-day, 12-month and up to 2-year (longest available follow-up)
Incidence of stroke
30-day, 12-month and up to 2-year (longest available follow-up)
Pace-maker implantation
Délai: 30-day, 12-month
Need for permanent pacing
30-day, 12-month
Vascular complications
Délai: 30-day
Incidence of vascular complications as defined by the VARC
30-day
Bleedings
Délai: 30-day
Incidence of bleedings as defined by the VARC
30-day
Acute kidney injury
Délai: 30-day
Incidence of AKI as defined by the VARC
30-day
Follow-up costs
Délai: 12-month
Evaluation of costs during follow-up, including new hospital admissions, outpatient clinic and drugs
12-month

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 décembre 2011

Achèvement primaire (Réel)

1 janvier 2016

Achèvement de l'étude (Réel)

1 janvier 2016

Dates d'inscription aux études

Première soumission

8 mai 2013

Première soumission répondant aux critères de contrôle qualité

9 mai 2013

Première publication (Estimation)

13 mai 2013

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

15 novembre 2016

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 novembre 2016

Dernière vérification

1 novembre 2016

Plus d'information

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

3
S'abonner